Veeva debuts single app for managing clinical trial data

cloud data
Veeva Systems is launching a new app that combines several of its tools including coding, EDC, data cleaning and reporting. (Geralt / Pixabay)

Veeva Systems is launching a new cloud-based application that combines several of its tools including coding, EDC, data cleaning and reporting.

The new app will allow companies to manage study build through execution and achieve a complete and concurrent view of all clinical data within a trial, the company said.

Dubbed the Veeva Vault CDMS, the app was designed to provide a complete and concurrent view of data throughout the trial with one application for data capture, coding, cleaning, reporting and management on a daily basis versus waiting weeks or months.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“The industry can finally move away from the complex patchwork of systems and integrations that limit the ability to leverage the range of clinical data available throughout the course of a trial,” Henry Levy, a general manager for Veeva, said in a statement. “Veeva Vault CDMS will provide the key capabilities companies need to bring together all their clinical data so research teams can make faster, more informed decisions.”

In March, Veeva joined ICON, Medpace, PPD, PRA Health Sciences, Syneos Health and UBC to develop open technology standards aimed at transforming clinical trial operations in an effort to accelerate development. The group, known as Align Clinical CRO works to make it easier for sponsors and CROS to work together during clinical trials, while making the process cheaper, quicker and more effective.

Suggested Articles

Scott Gottlieb has slipped right back into his old ways, becoming "special partner" at his old life science VC firm New Enterprise Associates.

Novartis, Otsuka, Pfizer and Sanofi will use technology from Verily’s Project Baseline to carry out clinical studies in various disease areas.

Biotech-CRO hybrid Evotec is continuing its buying and collaborating strategy with its acquisition of U.S. biologics company Just Biotherapeutics.